Aztreonam

Osteomyelitis, Gonorrhea, Septicemia + 11 more
Treatment
11 FDA approvals
17 Active Studies for Aztreonam

What is Aztreonam

AztreonamThe Generic name of this drug
Treatment SummaryViolacein is an antibiotic used to treat bacterial infections in the brain, bladder, and kidneys. It is effective against some types of bacteria that are resistant to other antibiotics. However, it can lead to a new infection caused by other types of bacteria.
Azactamis the brand name
image of different drug pills on a surface
Aztreonam Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Azactam
Aztreonam
2009
15

Approved as Treatment by the FDA

Aztreonam, commonly known as Azactam, is approved by the FDA for 11 uses which include Communicable Diseases and Communicable Diseases .
Communicable Diseases
Communicable Diseases
Gram-Negative Bacterial Infections
Skin Infections
Septicemia
Abdominal Infection
Gynaecological infection
Lower Respiratory Tract Infection (LRTI)
Intraabdominal Infections
Urinary Tract Infections
Bronchitis

Effectiveness

How Aztreonam Affects PatientsAztreonam is a type of antibiotic that is effective in fighting a wide range of bacteria, particularly gram-negative aerobic bacteria (including Pseudomonas aeruginosa). It is also known as the "magic bullet" due to its strong effect against these types of bacteria. Aztreonam is more resistant to certain types of enzymes that can break down other beta-lactam antibiotics and so it is often used when other antibiotics are not effective. This drug works over a wide range of pH levels and in the presence of human serum and without oxygen.
How Aztreonam works in the bodyAztreonam works by blocking the synthesis of the cell wall of bacteria. It does this by targeting a protein called penicillin binding protein 3 (PBP3). This blocks the last stage of cell wall synthesis, leading to the bacteria cell's destruction. Aztreonam may also interfere with an inhibitor of an enzyme called autolysins, which further weakens the cell wall and leads to the bacteria's death.

When to interrupt dosage

The measure of Aztreonam is contingent upon the diagnosed circumstance, including Intraabdominal Infections, Gram-Negative Bacterial Infections and Lower Respiratory Tract Infection (LRTI). The dose of dosage shifts, as per the delivery technique (e.g. Injection, powder, lyophilized, for solution - Intramuscular; Intravenous or Powder, for suspension - Respiratory (inhalation)) detailed in the table beneath.
Condition
Dosage
Administration
Bronchitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Communicable Diseases
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Pseudomonas Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Cystic Fibrosis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Communicable Diseases
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Febrile Neutropenia
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Osteomyelitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Intraabdominal Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Septicemia
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Urinary Tract Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Gonorrhea
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Gram-Negative Bacterial Infections
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Arthritis, Infectious
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution
Osteomyelitis
100.0 mg/mL, 200.0 mg/mL, , 1000.0 mg, 2000.0 mg, 75.0 mg, 75.0 mg/mL, 500.0 mg
Injection, solution - Intravenous, , Intravenous, Injection, solution, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution - Intramuscular; Intravenous, Injection, powder, lyophilized, for solution, Powder, for solution, Powder, for solution - Respiratory (inhalation), Respiratory (inhalation), Powder, for suspension, Powder, for suspension - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution

Warnings

There are 20 known major drug interactions with Aztreonam.
Common Aztreonam Drug Interactions
Drug Name
Risk Level
Description
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Aztreonam.
Abacavir
Minor
Aztreonam may decrease the excretion rate of Abacavir which could result in a higher serum level.
Aclidinium
Minor
Aztreonam may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Aztreonam may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Aztreonam may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
image of a doctor in a lab doing drug, clinical research

Aztreonam Novel Uses: Which Conditions Have a Clinical Trial Featuring Aztreonam?

33 active investigations are analyzing the potential of Aztreonam to relieve Bone and Joint Infections, Cystic Fibrosis (CF) and Gram-Negative Bacterial Infections.
Condition
Clinical Trials
Trial Phases
Septicemia
1 Actively Recruiting
Not Applicable
Gram-Negative Bacterial Infections
0 Actively Recruiting
Cystic Fibrosis
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Communicable Diseases
0 Actively Recruiting
Osteomyelitis
0 Actively Recruiting
Intraabdominal Infections
1 Actively Recruiting
Not Applicable
Arthritis, Infectious
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Bronchitis
2 Actively Recruiting
Not Applicable
Febrile Neutropenia
3 Actively Recruiting
Phase 2, Not Applicable
Gonorrhea
0 Actively Recruiting
Osteomyelitis
4 Actively Recruiting
Phase 4, Phase 2, Not Applicable
Pseudomonas Infections
0 Actively Recruiting

Aztreonam Reviews: What are patients saying about Aztreonam?

4.3Patient Review
5/26/2016
Aztreonam for Urinary Tract Infection
I had to take this treatment for a UTI, and it was every bit as annoying as you might expect. However, I'm glad to report that it was also quite effective. I saw no negative side effects whatsoever.
3Patient Review
3/1/2009
Aztreonam for Pneumonia caused by the Bacteria Pseudomonas Aeruginosa
This caused swelling in my knees and some pretty debilitating joint pain.

Patient Q&A Section about aztreonam

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What kind of antibiotic is aztreonam?

"Aztreonam belongs to a class of medications called monobactam antibiotics. These drugs work by killing bacteria. However, they will not work against infections caused by viruses, such as colds and the flu."

Answered by AI

Is aztreonam a penicillin?

"Aztreonam is an antibiotic that can be given intravenously or intramuscularly. It was approved in 1986 for the treatment of Gram-negative bacterial infections. It is marketed as a safe alternative for patients with penicillin allergies."

Answered by AI

What bacteria does aztreonam treat?

"Aztreonam is an antibiotic usually used to treat infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa. These infections might include bone infections, endometritis, intra abdominal infections, pneumonia, urinary tract infections, and sepsis."

Answered by AI

Is aztreonam a strong antibiotic?

"Aztreonam has been shown to be at least as effective as cefamandole or more effective in urinary tract infections, and similar in efficacy to tobramycin or gentamicin."

Answered by AI

Clinical Trials for Aztreonam

Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Aztreonam clinical trials? We made a collection of clinical trials featuring Aztreonam, we think they might fit your search criteria.Go to Trials
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Image of Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center in Cleveland, United States.

Alio Smart Patch Monitoring for Cancer Patients

18 - 65
All Sexes
Cleveland, OH
Undergoing cancer treatment comes with various risks and side effects. This clinical trial aims to reduce those risks and side effects through continuous monitoring of vital signs and blood levels. The goal is to see if potential side effects can be identified and treated sooner. During this study, participants will wear an Alio Smartpatchâ„¢. The Alio Smartpatchâ„¢ is a wireless remote monitoring system. This device will measure participants' vital signs and blood levels. Participants will also be asked to use continuous glucose monitors to measure their glucose levels. The data collected on each participant from these devices will be remotely monitored at all times by clinical staff at a company known as Quantify Remote Care. If a participant's results look like they are experiencing a side effect, the participant will be contacted immediately by Quantify Remote Care team. The Quantify Remote Care team will function as an extension of the participant's cancer clinical team and will relay any significant issues back to them. Quantify Health also provides dietary and mental health support as needed for all participants.
Recruiting
Has No Placebo
Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer CenterAlberto Montero, MD, MBA
Image of Ronald Reagan UCLA Medical Center in Los Angeles, United States.

Next Day Clinic for Patient Care

18+
All Sexes
Los Angeles, CA
The Next Day Clinic (NDC) is a quality improvement initiative that will be launched and operated by UCLA Health starting July 22, 2024. Its goals are to improve patient care and safety and to maximize cost effectiveness. The way it does this is by identifying patients in the ED who would normally be admitted for low-acuity conditions, and diverting them to a high-acuity clinic the following day called the NDC. This will help decompress the ED and the hospital, and allow for overall higher quality care. The Health System has partnered with UCLA's Healthcare Value Analytics and Solutions \[UVAS\] group which specializes in these types of program evaluations. The analysis conducted by the study team will be used to directly inform NDC operations, scaling, and future plans.
Recruiting
Has No Placebo
Ronald Reagan UCLA Medical Center
Image of Boston Medical Center in Boston, United States.

Recovery Management Checkups for Opioid Use Disorder

18 - 65
All Sexes
Boston, MA
This project is a pilot study of an adapted intervention of an existing Opioid Use Disorder (OUD) treatment retention intervention called Recovery Management Checkups (RMC). This intervention has been adapted to better fit the experiences and unique issues of those that have been hospitalized with serious injection related infections (SIRI) based on the findings from a prior qualitative study from the principal investigator. This project plans to test the adapted intervention within a smaller group of participants to assess feasibility, acceptability, and calculate early findings of intervention efficacy. Hospitalizations for SIRIs are a unique entry point for patients to start their recovery journey with medications for OUD (MOUD), but many people do not remain on long-term treatment, despite evidence that indicates MOUDs reduce death and re-hospitalization after SIRIs. The study objectives are to: * Assess the implementation feasibility of the adapted RMC model for patients with SIRI and OUD. * Establish preliminary estimates of intervention efficacy. * Make further adaptions to the intervention that will reduce both known and unknown barriers to care and increase effectiveness in future larger scale trials. Findings from this pilot study will result in further intervention refinement to better fit the target population, and serve as the basis for a larger randomized control trial that will have aims focused on more in-depth analysis of the efficacy of this program
Recruiting
Has No Placebo
Boston Medical CenterSimeon Kimmel, MD
Have you considered Aztreonam clinical trials? We made a collection of clinical trials featuring Aztreonam, we think they might fit your search criteria.Go to Trials
Image of BayCare Health System in Clearwater, United States.

Machine Learning Monitoring for Clinical Deterioration

18+
All Sexes
Clearwater, FL
In this study, the investigators will deploy a software-based clinical decision support tool (eCARTv5) into the electronic health record (EHR) workflow of multiple hospital wards. eCART's algorithm is designed to analyze real-time EHR data, such as vitals and laboratory results, to identify which patients are at increased risk for clinical deterioration. The algorithm specifically predicts imminent death or the need for intensive care unit (ICU) transfer. Within the eCART interface, clinical teams are then directed toward standardized guidance to determine next steps in care for elevated-risk patients. The investigators hypothesize that implementing such a tool will be associated with a decrease in ventilator utilization, length of stay, and mortality for high-risk hospitalized adults.
Waitlist Available
Has No Placebo
BayCare Health System (+2 Sites)Dana P Edelson, MD, MSAgileMD, Inc.
Image of Alberta Health Services in Edmonton, Canada.

Short Antibiotic Treatment for Febrile Neutropenia

18+
All Sexes
Edmonton, Canada
Infections are a common complication in patients with cancer. They are a significant cause of complications and death in this population. Patients with cancer and low neutrophil counts due to chemotherapy or disease often have a fever and receive antibiotic treatment. The optimal duration of this treatment is largely unknown. Late, there have been some data suggesting the safety of early discontinuation of antibiotics, though most centers still give more prolonged antibiotic therapies in this situation. The unnecessary prolonged antibiotic use may increase infections with multi-drug-resistant bacteria, which carry a high death rate. Also, an increase in infections caused by Clostridioides difficile and an increase in fungal infections can happen. However, some are concerned that stopping antibiotics while the neutrophil count is still low will result in life-threatening infections. Our study aims to test whether shorter antibiotic treatment in these situations is as safe as more prolonged treatment, resulting in better antibiotic prescription practices in this population.
Recruiting
Has No Placebo
Alberta Health Services (+3 Sites)Shahid Husain, MD
Image of Vriginia Mason Medical Center in Seattle, United States.

Antibiotic Usage for Overactive Bladder

18+
All Sexes
Seattle, WA
Intradetrusor injection of onabotulinumtoxinA, which is performed through a cystoscopic procedure, has been demonstrated to be efficacious in the treatment of both neurogenic and non-neurogenic overactive bladder (OAB), and is FDA approved as a treatment for overactive bladder. Intradetrusor of onabotulinumtoxinA is currently standard of care of patients with OAB who have persistent OAB symptoms despite behavioral therapies and oral medication treatments for OAB. As one of the main adverse events associated with intradetrusor injection of onabotulinumtoxinA is UTI, and published guidelines for cystoscopic procedures with manipulation recommend the use of prophylactic antibiotics, a single dose of prophylactic antibiotic is administered prior to this procedure. However, these recommendations are primarily based on data from randomized controlled trials (RCTs) involving antimicrobial prophylaxis during transurethral resection of the prostate. A previously published prospective study demonstrated that the rate of post-procedural UTI did not differ amongst patients with neurogenic bladder who did not receive prophylactic antibiotics and were asymptomatic for UTI, regardless of whether they had sterile urine cultures or asymptomatic bacteriuria, suggesting that patients who are not symptomatic for UTI may not require antibiotic prophylaxis prior to intradetrusor onabotulinumtoxinA injection. Studies have reported that up to 50% of antibiotic usage is inappropriate, leading to unnecessary exposure of patients to potential complications of antibiotic therapy, including Clostridium difficile infection which can cause recurrent diarrhea that may progress to sepsis and death, increasing antibiotic resistances, as well as dermal/allergic and gastro-intestinal manifestations. Therefore, in an effort to optimize antibiotic use, the investigators propose a prospective, randomized study to formally evaluate the differences in UTI frequency in subjects who have a negative urinalysis and are not symptomatic for UTI and receive prophylactic antibiotics at the time of intradetrusor onabotulinumtoxinA injection compared to those who do not receive prophylactic antibiotics at the time of injection. The proposed study seeks to evaluate the current practice standard of antibiotic prophylaxis prior to intradetrusor onabotulinumtoxin injection.
Recruiting
Has No Placebo
Vriginia Mason Medical Center (+1 Sites)Justina Tam, MD
Have you considered Aztreonam clinical trials? We made a collection of clinical trials featuring Aztreonam, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security